The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma

Pathology and Oncology Research

Volumn 19, Issue 1, 2013, Pages 35-40

  Luo, Yanli ^a   Tian, Ling ^a   Feng, Ye ^a   Yi, Miaoying ^a   Chen, Xiafang ^a   Huang, Qian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Deletion; p16; p53; Pancreatic ductal adenocarcinoma; Polysomy; Prognosis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC MARKER; GENETIC RISK; HEMIZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MALE; NUMERICAL CHROMOSOME ABERRATION; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; POLYSOMY 17; POLYSOMY 9; PREDICTION; RISK FACTOR; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

ANEUPLOIDY; CARCINOMA, PANCREATIC DUCTAL; CHI-SQUARE DISTRIBUTION; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; GENE DELETION; GENES, P16; GENES, P53; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84873082161     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-012-9555-3     Document Type: Article

References (31)

1. Spratlin JL, Mulder KE (2011) Looking to the future: biomarkers in the management of pancreatic adenocarcinoma. Int J Mol Sci 12:5895-5907
2. Singh P, Srinivasan R, Wig JD (2011) Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Pancreas 40:644-652
3. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, Beger HG (1997) Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 57:1634-1637
4. Stathopoulos GP, Androulakis N, Souglakos J, Stathopoulos J, Georgoulias V (2008) Present treatment and future expectations in advanced pancreatic cancer. Anticancer Res 28:1303-1308
5. Cohenuram M, Saif MW (2007) Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP 8:4-15
6. Saif MW, Karapanagiotou L, Syrigos K (2007) Genetic alterations in pancreatic cancer. World J Gastroenterol 13:4423-4430
7. Martinez JD (2010) Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy. Future Oncol 6:1857-1862
8. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 54:3025-3033
9. Fry LC, Mönkemüller K, Malfertheiner P (2008) Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg 393:883-890
10. Garcea G, Neal CP, Pattenden CL, Steward WP, Berry DP (2005) Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 41:2213-2236
11. Talar-Wojnarowska R, Malecka-Panas E (2006) Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med Sci Monit 12:RA186-RA193
12. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in independent poor prognostic predictor. Nat Genet 8:27-32
13. Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, Schmiegel W (1996) Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 110:1215-1224
14. Ohtsubo K, Watanabe H, Yamaguchi Y, Hu YX, Motoo Y, Okai T, Sawabu N (2003) Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters. J Gastroenterol 38:663-671
15. Jeong J, Park YN, Park JS, Yoon DS, Chi HS, Kim BR (2005) Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer. Yonsei Med J 46:519-525
16. Kim HG, Yamal JM, Xu XC, Hu W, Boiko I, Linares A et al (2005) Cervical chromosome 9 polysomy: validation and use as a surrogate endpoint biomarker in a 4-HPR chemoprevention trial. Gynecol Oncol 99:S32-S37
17. Stoecklein NH, Luebke AM, Erbersdobler A, Knoefel WT, Schraut W, Verde PE et al (2004) Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol 22:4737-4745
18. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S (2008) Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 21:742-747
19. Shan Z, Wu P, Zheng S, Tan W, Zhou H, Zuo Qi H et al (2010) Wang, evaluation of upper urinary tract tumors by FISH in Chinese patients. Cancer Genet Cytogenet 203:238-246
20. Sobin LH, Gospodarowicz MK (2009) Wittekind C UICC-TNM Classification of Malignant Tumours. Wiley-Liss, New York, pp 132-135
21. Korshunov A, Sycheva R, Golanov A (2004) Molecular stratification of diagnostically challenging high-grade Gliomas composed of small cells: the utility of fluorescence in situ hybridization. Clin Cancer Res 10:7820-7826
22. Botti C, Pescatore B, Mottolese M, Sciarretta F, Greco C, Di Filippo F et al (2000) Incidence of chromosomes 1 and 17 aneusomy in breast cancer and adjacent tissue: an interphase cytogenetic study. J Am Coll Surg 190:530-539
23. Tsiambas E, Kravvaritis C, Tsounis D, Salemis NS, Niotis A, Niotis TH et al (2010) Correlation between different p53 expression patterns and chromosome 17 imbalances in pancreatic ductal adenocarcinoma based on tissue microarray analysis. J BUON 15:94-100
24. Kubiliun N, Ribeiro A, Fan YS, Rocha-Lima CM, Sleeman D, Merchan J et al (2011) EUS-FNA with rescue fluorescence in situ hybridization for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology results. Gastrointest Endosc 74:541-754
25. Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA et al (2009) Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol 10:267-277
26. Koka V, Potti A, Koch M, Fraiman G, Mehdi S, Levitt R (2002) Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma. Anticancer Res 22:1593-1597
27. Saxby AJ, Nielsen A, Scarlett CJ, Clarkson A, Morey A, Gill A, Smith RC (2005) Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol 29:1125-1134
28. Panani AD, Maliaga K, Babanaraki A, Bellenis I (2009) Numerical abnormalities of chromosome 9 and p16CDKN2A gene deletion detected by FISH in non-small cell lung cancer. Anticancer Res 29:4483-4487
29. Mariatos G, Gorgoulis VG, Zacharatos P, Kotsinas A, Vogiatzi T, Rassidakis G et al (2000) Expression of p16(INK4A) and alterations of the 9p21-23 chromosome region in non-small-cell lung carcinomas: relationship with tumor growth parameters and ploidy status. Int J Cancer 89:133-141
30. Bruyère H, Sutherland H, Chipperfield K, Hudoba M (2010) Concomitant and successive amplifications of MYC in APL-like leukemia. Cancer Genet Cytogenet 197:75-80
31. Zámečníkova A (2011) Chromosomal translocation t(1;9)(q24;q34) in acute lymphoblastic leukemia patient involving the ABL1 gene. Leuk Res 35:e149-e150